Evaluating the Short-term Renal and Systemic Effects of Dapagliflozin in Non-diabetic Patients With Stage IV CKD at Risk of ESKD Because of Severe Renal Insufficiency and Persistent Proteinuria
Latest Information Update: 15 May 2024
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Renal failure
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms ADAPT
- 08 May 2024 Status changed from active, no longer recruiting to completed.
- 05 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 May 2024.
- 05 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 May 2024.